Multivalent Streptococcus Vaccines
The invention is directed to immunogenic compositions, including vaccines, containing multivalent immunogenic composition comprising 25 different serotypes of capsular polysaccharides of S. pneumoniae . Compositions are preferably liquid and thermo stable for periods of time that allow for distribution and use. The invention is also directed to method for the manufacture and methods for the administration of 25 valent immunogenic compositions of S. pneumoniae.
1 . An immunogenic composition comprising at least 25 different serotypes of polysaccharides of S. pneumoniae serotypes coupled to carrier protein.
2 . The immunogenic composition of claim 1 , wherein one or more of the capsular polysaccharides are from about 10 kDa to about 50 kDa.
3 . The immunogenic composition of claim 1 , wherein one or more of the capsular polysaccharides from about 30 KDa to about 100 KDa.
4 . The immunogenic composition of claim 1 , wherein one or more of the capsular polysaccharides are from about 100 KDa to about 300 KDa.
5 . The immunogenic composition of claim 1 , wherein the carrier protein comprises CRM, purified CRM197, recombinantly produced CRM, tetanus toxoid fragments (TTHc), tetanus toxin, tetanus toxin heavy chain proteins, diphtheria toxoid, tetanus toxoid, Pseudomonas exoprotein A, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid (PT), Clostridium perfringens toxoid, Escherichia coli heat-labile toxin B subunit, Neisseria meningitidis outer membrane complex, protein PorB, Hemophilus influenzae protein D, Flagellin Fli C, Horseshoe crab Haemocyanin, RSV virus proteins, adenylate cyclase toxin (ACT), 69 KDa protein and Human Papilloma viral protein antigens or its VLP form, Hepatitis B core antigen or its VLP form or derivatives of HBsAg, and/or and fragments, derivatives, and modifications thereof.
6 . The immunogenic composition of claim 1 , wherein one or more of the polysaccharides are covalently coupled to a linker and the linker is coupled to the carrier protein.
7 . The immunogenic composition of claim 1 , which is a liquid.
8 . The immunogenic composition of claim 1 , which comprises from about 0.25 ml to about 1.0 ml per dose.
9 . The immunogenic composition of claim 1 , which comprises about 0.5 ml per dose.
10 . The immunogenic composition of claim 1 , which comprises 10 micrograms or less of total polysaccharides and protein per dose.
11 . The immunogenic composition of claim 1 , which comprises 4 micrograms or less of total polysaccharides and protein per dose.
12 . The immunogenic composition of claim 1 , wherein the carrier protein comprise from about 0.5% to about 0.7%, by weight, per dose.
13 . The immunogenic composition of claim 1 , which comprises about equal amount by weight of capsular polysaccharides to total carrier protein.
14 . The immunogenic composition of claim 1 , which comprises a greater amount by weight of capsular polysaccharides to total carrier protein.
15 . The immunogenic composition of claim 1 , further comprising of at least one adjuvant.
16 . The immunogenic composition of claim 15 , wherein the at least one adjuvant is selected from the group consisting of aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, a TLR7/8 agonist, and combinations thereof.
17 . The immunogenic composition of claim 16 , wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide.
18 . The immunogenic composition of claim 1 , wherein the at least 25 different serotypes of capsular polysaccharides of S. pneumoniae comprise serotypes: 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 12F, 14, 15A, 15B, 15C, 16F, 18C, 19A, 22F, 23F, 24F, 33F, and 35B.
19 . The immunogenic composition of claim 1 , which, upon administration to a subject, generates a minimal immune response to carrier protein as compared to the immune response to polysaccharide.
20 . The immunogenic composition of claim 1 , which provides effective treatment or prevention of infection by S. pneumoniae bacteria.
21 . The immunogenic composition of claim 1 , comprising a a pharmacologically acceptable carrier.
22 . The method for manufacture of the immunogenic composition of claim 1 , comprising:
activating carrier proteins to form activated carrier proteins;
reducing a disulfide of each carrier protein to create a sulfhydryl group; and
coupling capsular polysaccharides to the activated carrier proteins.
23 . The method of claim 18 , wherein the activated carrier proteins are selected from the group consisting of cross-reactive material (CRM197) obtained or derived from C. diptheriae , and recombinant CRM197 obtained or derived from P. fluorescens or E. coli.
24 . The method of claim 18 , further comprising coupling PEG spacers to the activated carrier proteins.
25 . An immunogenic composition comprising one or more polysaccharides of one of more different serotypes of S. pneumoniae coupled to carrier protein via adipic acid dihydrazide (ADH) linkers, wherein the one or more polysaccharides have a molecular weight of from about 100 KDa to about 300 KDa.
26 . The immunogenic composition of claim 25 , wherein the one or more of the ADH linkers are pegylated dihydrazide (HZ-PEG-HZ) linkers.
27 . The immunogenic composition of claim 25 , wherein the carrier protein comprises CRM, recombinantly produced CRM, or a domain of CRM.
28 . A method of manufacture of the immunogenic composition of claim 25 , comprising:
providing the one or more polysaccharides of one of more serotypes of S. pneumoniae and carrier protein;
activating the one or more polysaccharides and/or the carrier protein with pegylated-ADH linkers; and
linking the polysaccharides to carrier protein via carbodiimide chemistry.
29 . The method of claim 28 , wherein the carrier protein comprises CRM, recombinantly produced CRM, tetanus toxoid or toxoid fragments (TTHc), tetanus toxin, tetanus toxin heavy chain proteins, diphtheria toxoid, tetanus toxoid, Pseudomonas exoprotein A, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid (PT), Clostridium perfringens toxoid, or a combination thereof.
30 . The method of claim 28 , wherein the one or more serotypes comprise serotypes: 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 12F, 14, 15A, 15B, 15C, 16F, 18C, 19A, 22F, 23F, 24F, 33F, and 35B.